TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Asymptomatic Primary Hyperparathyroidism: A Prospective, Randomized Trial
Brief Summary: The present study is a randomized, controlled trial that investigates the effects of parathyroidectomy or medical observation in mild asymptomatic pHPT on morbidity and quality of life (QoL).


Options:
A: Inclusion Criteria:

* Untreated, asymptomatic pHPT
* 2.60\>S-Ca\<2.85 mmol/liter
* Age between 50 and 80 yr
* No medications interfering with Ca-metabolism
* Informed consent

Exclusion Criteria:

* Hyperparathyroid bone disease
* Previous operation in the neck
* Impaired kidney function
* Kidney stones
* Complicating medical conditions
* Psychiatric disorders
* Multiple endocrine neoplasia,
* Familial hypocalcuric hypercalcemia
* Familial HPT
B: Inclusion Criteria:

1. Be diagnosed with PHPT (inappropriate PTH level in the setting of a high or high-normal serum calcium level greater than or equal to 10.0 mg/dL).
2. Have at least one of the following symptoms affecting sleep: a) not feeling refreshed on awakening b) difficulty falling asleep c) waking up during the night d) have difficulty falling back asleep at night after awakening e) waking up too early in the morning f) excessive sleepiness during the day
3. Be considered an appropriate surgical candidate.
4. Be older than 21 years of age.
5. Female participants of childbearing potential must have a negative pregnancy test (urinary or serum beta-HCG).

Exclusion Criteria:

1. Have a known major sleep disorder documented by prior diagnosis, such as: a) sleep disordered breathing b) narcolepsy c) periodic limb movement disorder d) parasomnias
2. Have any other functional tumors if they have familial Multiple Endocrine Neoplasia Syndrome 1 or 2 (MEN 1 or MEN 2).
3. Patients with a calcium level greater than 13mg/dL.
4. Patients with recent history of kidney stones.
5. Patients with recent history of pancreatitis
C: Inclusion Criteria:

* Primary hyperparathyroidism
* Referred to Aarhus University Hospital with the diagnose; primary hyperparathyroidism
* Participant is over 18 years old, able to understand and sign consent form

Exclusion Criteria:

* Familial hypocalciuric hypercalcaemia
* Multiple endocrine neoplasia (MEN)
* Parathyroid cancer
* Renal disease - GFR \< 60 ml/min
* Major heart surgery
* Known coronary heart disease
* NYHA III-IV
* Known with pacemaker
* Arrhythmia e.g. atrial fibrillations or flutter, Second- and third-degree atrioventricular block, sinoatrial depolarization of \< 40 or \> 160 beats per minute.
* Ongoing treatment with beta-blockers
* Severe manifest osteoporosis with multiple fractures
* Severe hypercalcemia: p-ionised calcium \> 1.70 mmol/L
D: Inclusion Criteria:

* Primary hyperparathyroidism subjected to parathyroid surgery

Exclusion Criteria:

* Renal insufficiency
* Severe osteoporosis
* Pregnancy

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Adolescent and Child Health Initiative to Encourage Vision Empowerment (ACHIEVE) Study
Brief Summary: The purpose of the study is to determine whether contact lens wear will improve children's self-perceptions more than spectacle wear.


Options:
A: Inclusion Criteria:

* all included patients, age from 6 to 15 years, had myopia (spherical equivalent \> -0.5 D) after cycloplegic refraction,
* The astigmatism and anisometropia were less than 2.0 D,
* IOP was less than 21 mmHg.

Exclusion Criteria:

* the presence of related disease such as infection, ulceration, eyelid disease, ocular and auricular disorders,
* individuals with amblyopia or strabismus,
* individuals received any other therapies in the period of study,
* individuals suffering some sort of haemostasis disorder,
* individuals did not follow the treatment (eyedrops and/or stimulation of auricular acupoints) over seven days
B: Inclusion Criteria:

* Age: 8 to 13 years
* Myopia: -1.00 to -5.00 D
* Myopia progression: at least 0.50 D/yr
* Astigmatism and anisometropia: not more than 1.50 D
* Distance monocular visual acuity: 6/6 or better
* Near monocular visual acuity: 0.4 M or better
* Stereoacuity: not more than 40 sec of arc at 40 cm

Exclusion Criteria:

* Strabismus
* Ocular diseases
C: Inclusion Criteria:

* 1.00 to 6.00 D spherical component myopia, based on cycloplegic autorefraction
* 1.00 DC or less astigmatism, based on cycloplegic autorefraction
* 20/20 or better best-corrected visual acuity in each eye
* Global stereoacuity of 250 seconds of arc or better based on Randot stereoacuity

Exclusion Criteria:

* Contact lens wear within the past month
* Ocular health problems that could affect vision, eye development, or contact lens wear
* Systemic health problems that could affect understanding of surveys or contact lens wear
* Participation in other eye or vision studies that prescribed a treatment
D: Inclusion Criteria:

* Refractive error determined by cycloplegic autorefraction which meets all of the following:

  1. Spherical equivalent: -0.50 to -3.00 D in both eyes
  2. Astigmatism \<= 1.5 D in both eyes
  3. Anisometropia \<= 1.00 D difference between eyes in spherical equivalent
* Visual acuity is at least 20/20 with best subjective refraction in both eyes
* Accommodative response at near (33 cm) is less than 2.0D by non-cycloplegic autorefraction
* Near esophoria (\>= 2.0 PD) present by alternate prism and cover test (APCT) at near using best refractive correction determined from non-cycloplegic subjective refraction

Exclusion Criteria:

* Strabismus present by cover-uncover test at far, near, and/or near with +2.00D over best subjective refraction
* Current or prior use of PALs, bifocals, or contact lenses in either eye (prior or current use of SVLs is allowed)

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Randomised Controlled Trial of Non-absorbable (Silk) Sutures Verses Absorbable (Vicryl) Sutures During the Surgical Treatment of Trachomatous Trichiasis
Brief Summary: Trachoma is the leading infectious cause of blindness worldwide. Recurrent infection by Chlamydia trachomatis causes in-turning of the eyelids / lashes (trichiasis), leading to corneal damage and blindness. The WHO recommends corrective eyelid surgery for trichiasis. Unfortunately, trichiasis frequently returns following surgery. The purpose of this study is to compare the outcome of surgery (at one and two years) for trichiasis using two currently used alternative suture types: non-absorbable (silk) and absorbable (vicryl). We, the researchers, hypothesise that the supportive presence of the absorbable suture for a longer period produces more stable wound healing, leading to a better outcome.


Options:
A: Inclusion Criteria:

* Major trichiasis: more than 5 lashes touching the eye

Exclusion Criteria:

* Previous eyelid surgery
B: Inclusion Criteria:

* Presence of upper lid trichiasis: defined by at least one eyelash touching the globe of the eye or evidence of epilation
* No previous report of trichiasis surgery in at least one eye with trichiasis:

  * eyes with prior surgery are already at high risk due to the prior surgery, and their inclusion may decrease our ability to clearly evaluate our primary outcome
  * if unilateral surgery has been performed previously, only the eye without prior history of surgery will be in the study, even if both eyes require surgery
* Age 18 or older (in order to provide consent as an adult): the vast majority of trichiasis patients are aged 18 or older
* At time of enrollment, subjects must state their intention to remain in the area for two years to facilitate study follow-up

Exclusion Criteria:

* Absence of upper lid trichiasis
* Prior trichiasis surgery on both eyes
* Age 18 or younger
* Subjects who are transiently in the area
C: Inclusion Criteria:

* Presence of trichiasis:
* no previous report of trichiasis surgery in at least one eye with trichiasis:
* Agreement by at least one other family member accompanying the patient that, if the patient is randomized to the family-treatment arm, s/he also would be willing to receive antibiotic treatment
* Age 18 or older

Exclusion Criteria:

* other household members concurrently participating in the trial
* Self-reported pregnancy
* Documented allergy to tetracycline
* Plans to move out of the region within 1 year.
D: Inclusion Criteria:

* Minor trichiasis: 1 - 5 lashes touching the eye

Exclusion Criteria:

* Previous eyelid surgery.
* Patients with evidence of corneal damage (will be offered surgery).

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Single-centre, Randomised, Single-blind, Parallel Group Clinical Trial in Rural Malawi, Testing the Growth Promoting Effect of Long-term Complementary Feeding of Infants With a High-energy, Micronutrient Fortified Spread
Brief Summary: This study tests the hypothesis that infants receiving milk-powder containing fortified spread (lipid-based nutrient supplement) as a complementary food for one year have lower incidence of severe stunting (poor length gain) than infants who are provided with no extra food supplements or maize-soy flour for complementary porridge.


Options:
A: Inclusion Criteria:

* Signed informed consent from at least one guardian
* Age 5.50 months to 6.49 months
* Availability during the period of the study.
* Permanent resident of Lungwena Health Centre or Malindi Hospital catchment area

Exclusion Criteria:

* Existing or imminent severe stunting (HAZ \< -2.8)
* Weight for length (WFH) \< 80% of the reference median or presence of oedema
* Severe illness warranting hospital referral.
* History of allergy towards peanut
* History of anaphylaxis or serious allergic reaction to any substance, requiring emergency medical care
* Concurrent participation in any other clinical trial
B: Inclusion Criteria:

* Confirmed maternal HIV-infection
* Age 5.5-6.5 months at intervention start
* Weight-for-length z-score \> -3 SD (WHO 2006 reference)

Exclusion Criteria:

* Confirmed or suspected allergy to peanuts
* Participation in a concurrent clinical trial at GHESKIO
C: Inclusion Criteria:

* Infants 6 to 12 months old
* Lives in Fort San Michel

Exclusion Criteria:

* Moderately or severely malnourished
* Peanut allergy
D: Inclusion Criteria:

* All children resident in randomized villages 6-59 months

Exclusion Criteria:

* N/A

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Double-Blind Placebo Controlled Randomized Trial of Montelukast in Acute Respiratory Syncytial Virus Bronchiolitis
Brief Summary: There is evidence of inflammatory mechanisms in RSV bronchiolitis with increased cysteinyl-leukotrienes (cys-LT). Recently, specific cys-LT receptor antagonists - montelukast (Singulair©) approved for use in infants as granule sachets, have become available. We evaluated the effect of Singulair© on clinical progress and on cytokine profiles in the acute phase of RSV bronchiolitis.


Options:
A: Inclusion Criteria:

* Age \> 4 weeks \< 2 years
* Duration of respiratory symptoms \< 4 days
* Signs of bronchiolitis: prodromal rhinorrhea and cough, followed by at least two of the following signs: chest retractions, tachypnea, wheezing, or rales
* First episode of wheezing or shortness of breath
* Randomization within 12 hours of admission
* No need for steroid treatment in the ward
* Informed consent

Exclusion Criteria:

* A history of asthma symptoms or any previous hospital admissions with respiratory tract illnesses and if they had ever been treated with anti-asthma medications (prior to the current illness).
* Underlying cardiopulmonary disease such as bronchopulmonary dysplasia, congenital heart disease, immunodeficiency, or cystic fibrosis.
B: Asthmatic children from birth to 18 years. Emphasis is placed on infants and young children through 5 years of age.
C: Inclusion Criteria:

* at least one physician-diagnosed wheezing episode and history of recurrent cough, dyspnoea and wheeze and successfully performed methacholine challenge test were included.

Exclusion Criteria:

* use of ICS within 8 weeks prior to the first visit, a cumulative life-time systemic prednisolone use more than 3 days at a dose of 2 mg/kg, an equipotent dose of another systemic corticosteroid or ICS use more than 4 weeks, respiratory infection in the 14 days preceding lung function measurement and obvious tracheobronchomalacia or other structural defect.
D: Inclusion Criteria:

* Hospitalized or in an urgent/emergent-care setting at least 24 hours for a first or second episode of RSV-induced bronchiolitis. Approximately twenty percent of patients will be allowed in the study with a stay of less than 24 hours but need to meet a minimum predefined Respiratory Severity Score as required by the study.

Exclusion Criteria:

* Asthma or other wheezing disorder. The Primary Investigator will evaluate whether there are other reasons why a child may not participate.

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A 12-week Open-label, Randomised, Parallel-group, Multicentre, Phase IIIb Study to Compare the Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe and Simvastatin in Patients With Hypercholesterolaemia and CHD
Brief Summary: The purpose of this study is to determine whether treatment of Rosuvastatin (CRESTOR™) or Simvastatin given as monotherapy or given in combination with Ezetimibe, will lower the Low Density Lipoprotein Cholesterol (LDL-C) in patients with Hypercholesterolaemia and Coronary Heart Disease (CHD) or a CHD Risk Equivalent, Atherosclerosis or a 10-year CHD Risk of \>20%


Options:
A: Men and women aged 18 to 69 years, with elevated cholesterol levels may be eligible to participate in a research study to assess the efficacy and safety of two marketed drugs.
B: Inclusion Criteria:

* Patients with with hypercholesterolaemia and CHD or a CHD risk equivalent, clinical evidence of atherosclerosis or a Framingham 10-year CHD risk score of \>20
* Patients will need to sign an informed consent before any visit procedures can be performed, including procedures for the optional genetic research and biomarker studies.
* Patients must be 18 years or older and will be asked to stop taking any current cholesterol-lowering medications. Dietary counselling will be provided which will include an overview of the Therapeutic Lifestyle Change (TLC) diet the patients will be asked to follow

Exclusion Criteria:

* Use of lipid lowering drugs and other prohibited concomitant medications. History of statin-induced myopathy, or serious hypersensitivity reaction to other HMG-CoA reductase inhibitors (statins), including rosuvastatin, simvastatin and/or a history of hypersensitivity to any components of ezetimibe.
* Patients considered to be unstable by their physician after the following events:

a myocardial infarction, recent episode of unstable angina, myocardial revascularisation \[percutaneous transluminal coronary angioplasty (PTCA), coronary artery bypass graft (CABG) surgery or another revascularisation procedure\] or a transient ischaemic attack (TIA) or stroke and patients awaiting a planned myocardial revascularisation
C: Inclusion Criteria:

* Non-ST segment elevation ACS and ST segment elevation ACS who receive optimal reperfusion therapy

Exclusion Criteria:

* Previous Q-wave infarct within the last 4 weeks
* CK elevation not caused by myocardial injury
* uncontrolled hypertension at time of randomization
D: Inclusion Criteria:

* Discontinuation of all cholesterol lowing drugs, including dietary supplements.
* Documented history of, or high risk of coronary heart disease or other established atherosclerotic disease.

Exclusion Criteria:

* The use of lipid lowering drugs or dietary supplements after Visit 1.
* Active arterial disease eg Unstable angina, or recent arterial surgery
* Uncontrolled hypertension, hypothyroidism, alcohol or drug abuse.
* Abnormal laboratory parameters as defined in the protocol.

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Randomized Controlled Trial of Routine Screening for Intimate Partner Violence
Brief Summary: This is a randomized controlled trial with three arms to establish the impact of screening and referral to services for women disclosing exposure to IPV.


Options:
A: Inclusion Criteria:

* women attending obstetrics \& gynecology (OB-GYN), family planning, general medicine, family medicine or HIV/Sexually transmitted disease (STD) clinic

Exclusion Criteria:

* non-English speaking other than Spanish speakers
* accompanied by a child \>3 years of age without adequate provision for child care;
* Visually- or hearing-impaired women;
* without access to a telephone;
* Severe Mental impairment
B: Inclusion Criteria:

* Child 0 - 5 years
* Family English speaking
* Parent agrees to participate

Exclusion Criteria:

* Child in foster care
* Another child in the family already enrolled
C: Inclusion Criteria:

* woman
* at least 18 years of age
* visiting one of the participant physicians
* in a current or recent intimate relationship during the last 12 months
* having the ability to speak and read English and give consent

Exclusion Criteria:

* visiting a provider other than the regular family physician
* new patient
* previously approached for the study
* very sick
* had a dual appointment (herself and accompanied dependent)
D: Inclusion Criteria:

* Resident of the village in which individual is studying (i.e., not a migrant scholar)
* Mature enough to understand the study and the consent process

Exclusion Criteria:

* N/A

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to evaluate the impact of a a real time teleassistance system in the clinical evolution of type 2 diabetic patients on self monitoring blood glucose in the Public National Primary Care System.


Options:
A: Inclusion Criteria:

* Diagnosis of type 2 Diabetes
* on SMBG al least 6 months before
* age superior of 30 years
* controlled in province of Málaga Primary Care Units

Exclusion Criteria:

* having diabetic complications or other diseases that could make difficult to use the telemedicine system
* patients who need a carer
* not passing the initial training (low cultural level)
* living in an area without mobile phone coverage
B: Inclusion Criteria:

* Type 2 diabetes
* age: 60 \~ 85 yrs
* HbA1c: 6.5%-11.0%
* duration of diabetes: less than 30 years
* BMI: 20-35

Exclusion Criteria:

* systemic corticosteroid administered within previous 6 months
* history of myocardial ischemia
* Heart failure, NYHA Class II-IV
* Thyroid disease with abnormal TFT
* Anti-obesity drugs or slimming products within previous 3 months
C: Inclusion Criteria:

* Age 55 years or greater
* Being a current Medicare beneficiary (verified by the Centers for Medicare and Medicaid Services)
* Having diabetes mellitus as defined by a physician's diagnosis and being on treatment with diet, an oral hypoglycemic agent, or insulin
* Residence in a federally designated medically underserved area (either of two federal designations, Medically Underserved Area \[MUA\] or Health Manpower Shortage Area \[HPSA\]) in New York Sate
* Fluency in either English or Spanish

Exclusion Criteria:

* Moderate or severe cognitive, visual, or physical impairment
* The presence of severe co-morbid disease.
D: Inclusion Criteria:

* Male or female subjects with type 1 or type 2 insulin-treated diabetes mellitus with a baseline HbA1c greater than or equal to 8.0%.
* The lower age limit for pediatric subjects was at the discretion of the pediatric investigators and their Institutional Review Board (IRBs).
* The upper age limit for pediatric subjects was 20 years (i.e., not having reached their 21st birthday on date of enrollment).
* Subjects must have monitored blood glucose at least 2 times per day. - Subject's current blood glucose meter has download capability, however, the subject did not routinely use this capability on his/her own.

Exclusion Criteria:

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Randomized Clinical Trial Comparing TVT SECUR System (TVT S) and Trans Vaginal Obturator Tape (TVT-O) for Surgical Management of Stress Urinary Incontinence
Brief Summary: To compare the efficacy and complications of the TVT SECUR system (TVT S) and trans-vaginal obturator tape (TVT-O) procedures for the surgical management of female stress urinary incontinence.


Options:
A: Inclusion Criteria:

* Female patients with symptoms of stress urinary incontinence and a positive cough test who require surgical management. Cough test is positive when leakage of urine is seen from the urethra synchronously with the patient performing a cough or valsalva manuver with a comfortably full bladder in the lying or standing position.

Exclusion Criteria:

* Women with predominantly symptoms of urge urinary incontinence
* Presence of prolapse greater than Pelvic organ prolapse quantification (POPQ) Stage 1 or prolapse requiring surgery
* Detrusor overactivity on cystometrogram at urodynamic testing
* Previous surgery for incontinence
* Intrinsic sphincter deficiency (MUCP\<20 cm H2O or Q -tip \<30o)
* Voiding dysfunction with postvoid residual \>100 cc
B: Inclusion Criteria:

* genuine stress incontinence

Exclusion Criteria:

* pregnancy
* \<12 months postpartum
* systemic disease and/or drugs known to affect bladder function
* current chemotherapy or radiation therapy
* urethral diverticulum
* augmentation cytoplasty
* artificial sphincter
* genital prolapse equal to or more than second degree
* history of severe abdominopelvic infections
* detrusor instability and/or intrinsic sphincter dysfunction
* other gynecologic pathologies
* BMI \>30
C: Inclusion Criteria:

* clinical and urodynamic diagnosis of SUI in patients between 18 and 90 years

Exclusion Criteria:

* postvoid residual urine volume more than 100 ml, coagulation disorders, current urinary tract infection, sequelae of previous radiation therapy of the pelvis, anticoagulant therapy, vulvovaginitis, and anesthesia contraindication
D: Inclusion Criteria:

Women with pure or predominant urodynamic stress urinary incontinence confirmed during filling cystometry by positive standardized cough stress test (CST) with urinary bladder filling of 250 ml in lithotomy position.

Exclusion Criteria:

* patients with predominant urge incontinence
* patients with intrinsic sphincter deficiency (MUCP\<20 cmH2O)
* pelvic organ prolapse (POP-Q\>2)
* previous urinary incontinence surgery
* previous pelvic organ prolapse surgery
* presence of other pelvic organ pathology.

Answer: A